Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LOX | P28300 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.38 |
| ▸ | IDE | P14735 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30628286 | 1.00 | ALDH1A1 (0.42) | ALDH1A1METSMN1; SMN2LOXLOXL2 | |
| SCHEMBL1272809 | 0.83 | NR1H2 (0.48) | — | |
| SCHEMBL10051059 | 0.83 | CA1 (0.55) | ALDH1A1METSMN1; SMN2LOXLOXL2 | |
| SCHEMBL30084552 | 0.81 | LMNA (0.54) | ALDH1A1SMN1; SMN2CA1CA2GAA | |
| SCHEMBL3677379 | 0.81 | LMNA (0.54) | ALDH1A1SMN1; SMN2CA1CA2GAA | |
| SCHEMBL8960195 | 0.79 | CA1 (0.41) | ALDH1A1SMN1; SMN2CA1CA2HSD17B10 | |
| SCHEMBL22619100 | 0.78 | PSIP1 (0.56) | ALDH1A1SMN1; SMN2CA1CA2GAA | |
| SCHEMBL18948539 | 0.77 | CA1 (0.44) | ALDH1A1METSMN1; SMN2LOXLOXL2 | |
| SCHEMBL3919478 | 0.77 | CA2 (0.70) | CA1CA2 | |
| SCHEMBL19122490 | 0.77 | CA2 (0.39) | ALDH1A1SMN1; SMN2CA1CA2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250233-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2025-08-07 | — | — | US | disclosed |
| EP-4519246-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE | Prilenia Neurotherapeutics Ltd. (IL) | 2025-03-12 | — | — | EP | disclosed |
| WO-2023214412-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2023-11-09 | — | — | WO | disclosed |
| CN-111170991-B | Antiproliferative compounds and methods of synthesis thereof | 细胞基因公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-3594211-B1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20220387413-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2022-12-08 | — | — | US | disclosed |
| US-11241423-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
| US-11136337-B2 | Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-10-05 | — | — | US | disclosed |
| US-20210040113-A1 | PYRAZOLE- AND INDAZOLE- SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2021-02-11 | — | — | US | disclosed |
| EP-3733670-A1 | TETRAHYDROPYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | Mediconns (Shanghai) Biopharmaceutical Co., Ltd (CN) | 2020-11-04 | — | — | EP | disclosed |
| US-20130261317-A1 | METHODS FOR PREPARING SYNTHETIC BILE ACIDS AND COMPOSITIONS COMPRISING THE SAME | KYTHERA BIOPHARMACEUTICALS, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| EP-2237779-A1 | BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND METHODS OF USE | Abbott Laboratories (US) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009085945-A1 | BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2007050348-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| CN-1028521-C | Therapeutic agents | BOOTS CO PLC (GB) | 1995-05-24 | — | — | CN | disclosed |
| EP-0536151-B1 | ORTHOSUBSTITUTED BIPHENYL GUANIDINE DERIVATIVES AND ANTIDIABETIC OR HYPOGLYCAEMIC AGENTS CONTAINING THEM | BOOTS CO PLC (GB) | 1994-09-14 | — | — | EP | disclosed |
| US-5302720-A | Biphenyl-substituted guanidine derivatives useful as hypoglycaemic agents | THE BOOTS COMPANY (GB) | 1994-04-12 | — | — | US | disclosed |
| CN-1072173-A | Therapeutical agent | BOOTS CO PLC (GB) | 1993-05-19 | — | — | CN | disclosed |
| EP-0536151-A1 | ORTHOSUBSTITUTED BIPHENYL GUANIDINE DERIVATIVES AND ANTIDIABETIC OR HYPOGLYCAEMIC AGENTS CONTAINING THEM. | BOOTS CO PLC (GB) | 1993-04-14 | — | — | EP | disclosed |
| WO-1992000273-A1 | ORTHOSUBSTITUTED BIPHENYL AMIDINE AND BIPHENYL GUANIDINE DERIVATIVES AND ANTIDIABETIC OR HYPOGLYCAEMIC AGENTS CONTAINING THEM | THE BOOTS COMPANY PLC (GB) | 1992-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261317-A1 | METHODS FOR PREPARING SYNTHETIC BILE ACIDS AND COMPOSITIONS COMPRISING THE SAME | HSD17B11, DHCR7, CYP46A1 | ALDH1A1 1917/4885MET 2153/4885SMN1; SMN2 4372/4885 |
| US-20220387413-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | ALDH1A1 247/4885MET 1414/4885SMN1; SMN2 289/4885 |
| US-11241423-B2 | Antiproliferative compounds and methods of use thereof | MCL1, MKI67, BAX | ALDH1A1 247/4885MET 1414/4885SMN1; SMN2 289/4885 |
| US-20250250233-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE | QDPR, MAOB, DRD2 | ALDH1A1 1588/4885MET 4767/4885SMN1; SMN2 2252/4885 |
| US-20210040113-A1 | PYRAZOLE- AND INDAZOLE- SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | GIPR, GPR119, MBOAT4 | ALDH1A1 347/4885MET 2368/4885SMN1; SMN2 4544/4885 |
| US-11136337-B2 | Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors | GIPR, GPR119, MBOAT4 | ALDH1A1 347/4885MET 2368/4885SMN1; SMN2 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.